


NYHA). 50 III-IV (,
 () <35%)
 . 6 ,
 ; 1
 , ()
 5-10 , - ()
 2,5 5-10 ,
 12,5 / () . 1
 (2 : 25 (,) ,)
 25 ()
 40 . 5 .
 6- , -1
 (-1) 6- - 1 .
 , - « »
 (-) . -1
 (-1), -6 (-6), -8 (-8)
 (- 1).
 3,5 MHz «ULTIMA PRO-30» (« » ,).
 Statistica for Windows 6.0.
 (-) ,
 (50-) 25- 75- () .
 : () -
 ; -
 - .
 2- : 2
 48 - 23 , 25 - ,
 -
 , , ,
 , 1 ,
 () () () ,
 . 41,5% .

(< 100 /) 1
 5 (20%), 5 - 24 (96%) (. 1).




* - (< 0,05)

y I -


32% 16% () ()
 44,2 /) (< 0,05), 12% (39,5 /
 2% (> 0,05).
 (< 39 /), 5

(. 2).
 3, -1, 4
 6- - 1.
 1, 6- - 1,
 -1, 1, 6- - 1,
 (5 .)
 6- - 1 71,6 /
 86,7 / , -1 13,2 / 11,5 / ,
 6- - 1
 14,6 / 68,5 / 110,5 / , -1
 9,8 / . 6- - 1
 22,3%,
 61,3%, -1 12,9% 32,9%.
 (< 0,05).



2 -

.3.



* -

(* - <0,05; ** - <0,01)

3 -

5. (. . .) / // -2009. - . 10, 2 (52). - . 64-106.
6. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of ω -3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure / L. Tavazzi, G. Tognoni, M.G. Franzosi et al. // *Eur. J. Heart Fail.* - 2004. - Vol. 6. - P. 635-641.
7. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics / J. Kjekshus, P. Dunselman, M. Blideskog et al. // *Eur. J. Heart Fail.* - 2005. - Vol. 7. - P. 1059-1069.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial // *Lancet.* - 2003. - Vol. 361. - P. 2005-2016.
9. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure / S.D. Katz, K. Hryniewicz, I. Hriljac et al. // *Circulation.* - 2005. - Vol. 111. - P. 310-314.
10. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide / A.Y. Chong, A.D. Blann, J. Patel et. al. // *Circulation.* - 2004. - Vol. 110. - P.1794-1798.
11. Rikitake Y. Pases, statins, and nitric oxide / Y. Rikitake, J.K. Liao, G.T. Rho // *Circ. Res.* - 2005. - Vol. 97. - P.1232-1235.
12. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins / F.W. Asselbergs, P. Van der Harst, G.A.J. Jessurun, R.A. Tio, W.H. Van Gilst // *Vascul. Pharmacol.* - 2005. - Vol. 42. - P.125-140.

12 2010 .